Kymera Therapeutics (KYMR)
(Real Time Quote from BATS)
$48.79 USD
-0.96 (-1.93%)
Updated Aug 27, 2024 02:45 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Kymera Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 375 | 407 | 442 | 296 | 92 |
Receivables | 15 | 0 | 0 | 1 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 15 | 12 | 9 | 6 | 1 |
Total Current Assets | 405 | 419 | 451 | 302 | 93 |
Net Property & Equipment | 48 | 13 | 12 | 11 | 4 |
Investments & Advances | 61 | 152 | 125 | 163 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 8 | 9 | 8 | 2 | 2 |
Total Assets | 576 | 603 | 606 | 487 | 117 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 4 | 4 | 4 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 1 | 1 | 1 | 1 | 1 |
Accrued Expenses | 34 | 28 | 23 | 10 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 38 | 36 | 62 | 93 | 23 |
Total Current Liabilities | 86 | 71 | 93 | 111 | 35 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 17 | 28 | 39 | 78 | 30 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 1 | 1 | 1 | 1 | 1 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 181 | 113 | 146 | 203 | 82 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 109 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 926 | 879 | 689 | 413 | 2 |
Retained Earnings | -531 | -384 | -229 | -129 | -76 |
Other Equity | -1 | -5 | -1 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 395 | 490 | 460 | 284 | 35 |
Total Liabilities & Shareholder's Equity | 576 | 603 | 606 | 487 | 117 |
Total Common Equity | 395 | 490 | 460 | 284 | -74 |
Shares Outstanding | 55.40 | 54.80 | 51.30 | 44.40 | NA |
Book Value Per Share | 7.13 | 8.94 | 8.96 | 6.39 | 0.00 |
Fiscal Year End for Kymera Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 510 | 521 | 375 | 358 | 368 |
Receivables | 0 | 0 | 15 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 15 | 17 | 15 | 18 | 18 |
Total Current Assets | 525 | 537 | 405 | 376 | 385 |
Net Property & Equipment | 52 | 49 | 48 | 36 | 27 |
Investments & Advances | 192 | 224 | 61 | 77 | 105 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 8 | 8 | 8 | 9 | 9 |
Total Assets | 826 | 868 | 576 | 552 | 582 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 7 | 7 | 5 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 1 | 1 | 1 | 1 | 1 |
Accrued Expenses | 24 | 16 | 34 | 26 | 22 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 19 | 23 | 38 | 28 | 25 |
Total Current Liabilities | 62 | 56 | 86 | 63 | 55 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 3 | 24 | 17 | 16 | 20 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 1 | 1 | 1 | 1 | 1 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 141 | 157 | 181 | 157 | 147 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,308 | 1,292 | 926 | 914 | 903 |
Retained Earnings | -621 | -579 | -531 | -516 | -464 |
Other Equity | -2 | -2 | -1 | -2 | -4 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 685 | 711 | 395 | 396 | 435 |
Total Liabilities & Shareholder's Equity | 826 | 868 | 576 | 552 | 582 |
Total Common Equity | 685 | 711 | 395 | 396 | 435 |
Shares Outstanding | 61.30 | 61.30 | 55.40 | 55.40 | 55.40 |
Book Value Per Share | 11.17 | 11.60 | 7.13 | 7.14 | 7.86 |